Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Columbia Licenses Novel 3-D Organ and Tumor Segmentation Software to Varian Medical Systems

Published: Friday, May 17, 2013
Last Updated: Friday, May 17, 2013
Bookmark and Share
Allows for more precise and efficient planning and monitoring of cancer treatment.

Columbia University has signed a licensing agreement with Varian Medical Systems for novel imaging software that facilitates 3-D segmentation, the process by which anatomical structures in medical images are distinguished from one another—an important step in the precise planning of cancer surgery and radiation treatments.

“Organ- and tumor-specific segmentation is fundamental for proper radiation treatment planning and follow-up in cancer patients,” said Lawrence Schwartz, MD, professor and chair of the Department of Radiology, Columbia University Medical Center, who has extensive experience in both conventional and novel imaging techniques. “Our algorithms have been developed in response to the growing demand for quantitative imaging techniques that provide more accurate organ/tumor delineation and tumor response criteria. At the Computational Image Analysis Laboratory, led by Binsheng Zhao, DSc, professor of clinical radiology, we have incorporated advanced methodologies to address these needs. Columbia is pleased to have established a relationship with Varian, a manufacturer of treatment devices.”

Three-D segmentation of CT and MR images provides a reliable way to identify organs such as the liver, spleen, and kidneys. Determining organ and tumor contours and volumes (including those of primary and metastatic tumors) before, during, and after treatment can be challenging. Accurate and efficient characterization of these diverse structures is necessary to enable noninvasive assessments in clinical practice and clinical trials, as well as in radiation treatment planning.

“Modern radiation treatment planning requires careful delineation of the targeted tissue, as well as the critical structures to be avoided,” said Jeff Amacker, senior director of clinical solutions at Varian. “We hope that our collaborative efforts with Columbia University Medical Center’s radiology department will lead to improved patient care by providing new tools and automation for the precise planning of radiation treatments.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Two Treatments for Retinitis Pigmentosa Move Closer to Clinical Trials
One treatment involves skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy.
Friday, December 21, 2012
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!